Trial Profile
An evaluation of the safety and tolerability of different doses of (open study section) HLX02 in Chinese healthy male subjects compared HLX02 and Herceptin (in USA and Germany) the pharmacokinetics, safety phase I clinical study, tolerability and immunogenicity: randomized, double-blind, parallel-group portion
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Apr 2016
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 29 Apr 2016 New trial record